{"pre_text": ["alexion pharmaceuticals , inc .", "notes to consolidated financial statements 2014 ( continued ) for the years ended december 31 , 2007 and 2006 , five month period ended december 31 , 2005 , and year ended july 31 , 2005 ( amounts in thousands , except share and per share amounts ) aggregate future minimum annual rental payments for the next five years and thereafter under non-cancellable operating leases ( including facilities and equipment ) as of december 31 , 2007 are: ."], "post_text": ["9 .", "commitments and contingencies legal proceedings on march 16 , 2007 , pdl biopharma , inc. , or pdl , filed a civil action against alexion in the u.s .", "district court for the district of delaware .", "pdl claims willful infringement by alexion of pdl patents due to sales of soliris .", "pdl seeks unspecified damages , but no less than a reasonable royalty , plus attorney 2019s fees .", "alexion has denied pdl's claims .", "in addition , we filed counterclaims seeking declarations of non-infringement and invalidity of certain u.s .", "patents held by pdl .", "alexion believes it has good and valid defenses to pdl's claims and intends to vigorously defend the case and pursue its counterclaims .", "on february 4 , 2008 , sb2 , inc .", "filed a civil action against alexion in the united states district court for the northern district of california .", "sb2 , inc .", "claims willfull infringement by alexion of sb2 , inc .", "patents due to sales of soliris .", "sb2 , inc .", "seeks unspecified monetary damages , equitable relief and attorneys fees .", "alexion believes it has good and valid defenses to sb2's claims and intends to vigorously defend the case and pursue its counterclaims .", "the results of such civil actions cannot be predicted with certainty due to their early stages .", "however , depending on the outcome of these legal matters , the operating results of the company could be materially impacted through adjustments to cost of sales ( see notes 2 , 6 and 15 for additional information related to royalties ) .", "product supply the large-scale product supply agreement dated december 18 , 2002 , or the lonza agreement , between lonza sales ag , or lonza , and us , relating to the manufacture of soliris , was amended in june 2007 .", "we amended our supply agreement to provide for additional purchase commitments of soliris of $ 30000 to $ 35000 through 2013 .", "such commitments may only be cancelled in limited circumstances. ."], "table": [["2008", "$ 4935"], ["2009", "3144"], ["2010", "3160"], ["2011", "3200"], ["2012", "2768"], ["thereafter", "9934"]], "table_ori": [["2008", "$4,935"], ["2009", "3,144"], ["2010", "3,160"], ["2011", "3,200"], ["2012", "2,768"], ["Thereafter", "9,934"]]}

Question: what is the average future minimum annual rental payment for the next five years?
Evidence:
table_1: 2008 the 2009 of $ 4935 is 3144 ;
table_2: 2008 the 2010 of $ 4935 is 3160 ;
table_3: 2008 the 2011 of $ 4935 is 3200 ;
table_4: 2008 the 2012 of $ 4935 is 2768 ;
text_1: notes to consolidated financial statements 2014 ( continued ) for the years ended december 31 , 2007 and 2006 , five month period ended december 31 , 2005 , and year ended july 31 , 2005 ( amounts in thousands , except share and per share amounts ) aggregate future minimum annual rental payments for the next five years and thereafter under non-cancellable operating leases ( including facilities and equipment ) as of december 31 , 2007 are: .
table_5: 2008 the thereafter of $ 4935 is 9934 ;
Program: add(3144, 3160), add(#0, 3200), add(#1, 2768), add(#2, 9934), divide(#3, const_5)
Answer:
str_answer: 4441
exe_answer: 4441.2